Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AVE1642 · 1 trial · 1 indication
Selected Dose will be based on the AVE1642 clearance /IGF-1 plateaus and on safety (less than 33% of pts with dose limiting toxicity (DLT)when administered as single agent in a first part of the study. The safety and pharmacokinetics of the regimen in combination with bortezomib will be assessed in the second part of the study
| Arm | Type | Description |
|---|---|---|
| AVE1642/ AVE1642 with Velcade | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| AVE1642 | DRUG | For Part 1, AVE1642 was administered on Day 1 and then every three weeks intra-venously with the dose escalation step starting at 3 mg/kg/infusion with a classical dose escalation schema of 3+3. For Part 2, AVE1642 was administered at doses ranging from 0.5 mg/kg to 12 mg/kg |
| Velcade | DRUG | For Part 2 ONLY, fixed dose of 1.3 mg/m² administered on Days 1, 4, 8, and 11. |
Inclusion Criteria: * Multiple myeloma confirmed by bone marrow aspirate or biopsy * Patient had to have relapsed and/or refractory multiple myeloma after at least 1 standard therapy, and have demonstrated disease progression * Previous exposure to Velcade was allowed, provided no DLTs of Grade 3 o...
Top 20 of 25 competitors
AVE1642 is an investigational small molecule being studied for the treatment of multiple myeloma, a type of blood cancer. It is currently in Phase 1 clinical development, meaning it is still being tested in clinical trials and is not yet approved for use.
AVE1642 is an anti-IGF1R monoclonal antibody, meaning it targets the insulin-like growth factor 1 receptor (IGF1R). By targeting this receptor, the drug aims to interfere with signaling pathways that may promote cancer cell growth in multiple myeloma.
AVE1642 is being developed by Sanofi, a global biopharmaceutical company. Sanofi's stock is listed under the ticker symbol SNY on the stock market.
AVE1642 is in Phase 1 of clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still undergoing clinical trials to evaluate its safety and efficacy in patients.
AVE1642 has one completed clinical trial, identified as NCT01233895, titled 'Study of AVE1642 Anti-IGF1R Monoclonal Antibody in Patients With Advanced Multiple Myeloma.' This Phase 1 trial enrolled 26 participants in France and Italy and has been completed.
Yes, AVE1642 is an anti-IGF1R monoclonal antibody. It is designed to target the insulin-like growth factor 1 receptor, which is a protein involved in cell growth and survival. This mechanism is being explored for its potential role in treating multiple myeloma.